BMO Capital on Biogen (BIIB): Apellis deal 'sets a clear path for further expansion in nephrology'
Tweet Send to a Friend
BMO Capital analyst Evan Seigerman reiterated a Market Perform rating and $196.00 price target on Biogen (NASDAQ: BIIB)The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
